Natera: Rowan Chapman
Rowan Chapman has joined the board of directors of Natera. Most recently, she was head of Johnson & Johnson Innovation for Western North America, Australia, and New Zealand; head of precision diagnostics at GE Healthcare Life Sciences; and managing director of new business creation and head of healthcare investing at GE Ventures. Prior to that, she was a partner at Mohr Davidow Ventures. Chapman holds a BA in biochemistry and a PhD in biochemistry and molecular biology from the University of Cambridge.
Illumina: Garret Hampton
Garret Hampton, senior vice president of clinical genomics at Illumina, will be leaving the company effective Jan. 10, 2020 "in connection with an organizational restructuring," the company said this week in a document filed with the US Securities and Exchange Commission. Illumina.
All of Us Research Program: Eric Dishman
Eric Dishman, director of the National Institutes of Health's All of Us Research Program, will step down from the role and serve as the program's chief innovation officer. In his new role, Dishman will drive the "strategic and user-centered development of new program features." Dishman, a cancer survivor, said this change would allow him to focus on his long-term health and direct his energies toward patient advocacy activities. The shift in leadership also marks an evolution for the All of Us program "from a startup to a more established organization," he noted. A nationwide search for a new director and CEO of the population health research effort will begin this week.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.